Mirum Pharmaceuticals Inc (MIRM)

May 19, 2025, 8:30 AM EDT - 14 days ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 14, 2025, 4:05 PM EDT - 18 days ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 9, 2025, 6:00 PM EDT - 23 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 8:30 AM EDT - 24 days ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 7, 2025, 9:17 PM EDT - 25 days ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 25 days ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 6:45 PM EDT - 4 weeks ago

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

Apr 30, 2025, 8:30 AM EDT - 4 weeks ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 8:30 AM EDT - 5 weeks ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 14, 2025, 8:30 AM EDT - 7 weeks ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Mar 27, 2025, 8:30 AM EDT - 2 months ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 24, 2025, 5:17 PM EDT - 2 months ago

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Feb 27, 2025, 7:10 AM EST - 3 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 3 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 3 months ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 21, 2025, 12:01 PM EST - 3 months ago

US FDA approves Mirum Pharma's genetic disorder drug

Feb 19, 2025, 4:04 PM EST - 3 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Jan 13, 2025, 8:30 AM EST - 5 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 8, 2025, 11:05 AM EST - 5 months ago

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 6, 2025, 4:04 PM EST - 5 months ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 25, 2024, 10:00 AM EST - 5 months ago

Mirum Pharma: Buy At Dips For Volixibat Potential

Nov 14, 2024, 8:00 AM EST - 7 months ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 12, 2024, 1:51 PM EST - 7 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:00 AM EST - 7 months ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 7 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 7 months ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Oct 10, 2024, 8:30 AM EDT - 8 months ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Aug 9, 2024, 9:10 PM EDT - 10 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 10 months ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:30 PM EDT - 10 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Jul 25, 2024, 8:30 AM EDT - 11 months ago

Mirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Jul 17, 2024, 3:48 AM EDT - 11 months ago

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 8, 2024, 8:30 AM EDT - 11 months ago

Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Jun 27, 2024, 4:48 PM EDT - 1 year ago

3 Biotech Stocks For The Second Half Of 2024

ALT NTLA

Jun 17, 2024, 10:53 AM EDT - 1 year ago

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Jun 16, 2024, 5:00 PM EDT - 1 year ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 31, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

May 29, 2024, 8:30 AM EDT - 1 year ago

Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

May 18, 2024, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

May 11, 2024, 2:25 PM EDT - 1 year ago

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:10 PM EDT - 1 year ago

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

FSV

May 1, 2024, 4:10 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Apr 22, 2024, 3:04 PM EDT - 1 year ago

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Mar 13, 2024, 6:49 PM EDT - 1 year ago

US FDA approves expanded use of Mirum's liver disease drug